Charles River Laboratories Intl. (NYSE: CRL) and RadNet (NASDAQ:RDNT) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, profitability, dividends, risk and analyst recommendations.
Institutional and Insider Ownership
99.8% of Charles River Laboratories Intl. shares are held by institutional investors. Comparatively, 56.5% of RadNet shares are held by institutional investors. 2.2% of Charles River Laboratories Intl. shares are held by insiders. Comparatively, 9.4% of RadNet shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
This table compares Charles River Laboratories Intl. and RadNet’s top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Charles River Laboratories Intl.||$1.86 billion||2.71||$123.35 million||$2.54||41.84|
Charles River Laboratories Intl. has higher revenue and earnings than RadNet. RadNet is trading at a lower price-to-earnings ratio than Charles River Laboratories Intl., indicating that it is currently the more affordable of the two stocks.
This table compares Charles River Laboratories Intl. and RadNet’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Charles River Laboratories Intl.||6.64%||26.14%||9.09%|
This is a summary of recent ratings and recommmendations for Charles River Laboratories Intl. and RadNet, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Charles River Laboratories Intl.||0||6||6||0||2.50|
Charles River Laboratories Intl. presently has a consensus price target of $115.83, indicating a potential upside of 9.00%. RadNet has a consensus price target of $14.67, indicating a potential upside of 7.84%. Given Charles River Laboratories Intl.’s higher probable upside, equities analysts clearly believe Charles River Laboratories Intl. is more favorable than RadNet.
Volatility & Risk
Charles River Laboratories Intl. has a beta of 0.71, meaning that its stock price is 29% less volatile than the S&P 500. Comparatively, RadNet has a beta of 0.69, meaning that its stock price is 31% less volatile than the S&P 500.
Charles River Laboratories Intl. beats RadNet on 12 of the 15 factors compared between the two stocks.
About Charles River Laboratories Intl.
Charles River Laboratories International, Inc. is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development. The Company operates in three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment includes Research Models and Research Model Services. The DSA segment includes Discovery Services and Safety Assessment. The Manufacturing segment includes Microbial Solutions, Avian, Biologics and Contract Manufacturing. The Company also provides a suite of products and services to support the Company’s clients’ manufacturing activities.
RadNet, Inc. is a provider of freestanding, fixed-site outpatient diagnostic imaging services in the United States. As of December 31, 2016, the Company operated directly or indirectly through joint ventures, 305 centers located in California, Delaware, Florida, Maryland, New Jersey, New York and Rhode Island. Its centers provide physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders. Its services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), fluoroscopy and other related procedures. As of December 31, 2016, the Company had in operation 257 MRI systems, 157 CT systems, 47 PET or combination PET/CT systems, 48 nuclear medicine systems, 479 X-ray systems, 279 mammography systems, 551 ultrasound systems and 104 fluoroscopy systems.
Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.